Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Evaluation of Transcranial Magnetic Stimulation for depression initiated in Denmark

On October 5, 2023, the Health Technology Council initiated the evaluation aimed to investigate whether Transcranial Magnetic Stimulation should be used as a treatment option for adult patients with treatment-resistant depression. The expected publication date is not announced yet.

The Health Technology Council launched in 2021 aimed to support the greater use of cost-effective technologies in the healthcare system through recommendations to regions and hospitals. The Council develops two types of reports: evaluations and major analyses. In both cases, there is a staged process: proposal, evaluation/analysis, decision, and implementation. However, there are differences: 2-3 ‘major analyses’ are developed annually on the fundamental topics (e.g., treatment regimens, approaches to the organization of treatments) proposed by hospitals or regions (not industry); up to 15-25 ‘evaluations’ can be developed annually regarding marketed medical devices and health technologies proposed by any stakeholder (including industry).

See the full details in Danish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.